Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in September.
H.C. Wainwright 22nd Annual Global Investment Conference
Company Presentation
Date: Wednesday, September 16, 2020
Time: 1:00 p.m. ET / 10:00 a.m. PT
Cantor Fitzgerald Virtual Global Healthcare Conference
Analyst-Led Fireside Chat
Date: Thursday, September 17, 2020
Time: 10:00 a.m. ET / 7:00 a.m. PT
About Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company’s lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005702/en/
Contacts
Company Contact:
Carmine Stengone
President and CEO
info@pipelinetherapeutics.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com
Source: Pipeline Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20200909005702/en
